Merck, Kelun trumpet Phase 3 breast cancer data for anti-TROP2 ADC

Mer­ck and Kelun-Biotech re­vealed Phase 3 breast can­cer da­ta for the lead an­ti­body-drug con­ju­gate in their po­ten­tial­ly $12 bil­lion part­ner­ship.

In a Phase 3 tri­al for lo­cal­ly re­cur­rent or metasta­t­ic triple-neg­a­tive breast can­cer, the an­ti-TROP2 ADC sac­i­tuzum­ab tiru­mote­can (pre­vi­ous­ly known as SKB264/MK-2870) re­duced pa­tients’ risk of dis­ease pro­gres­sion or death (PFS) by 69% com­pared with chemother­a­py. Ad­di­tion­al­ly, pa­tients’ over­all risk of death (OS) was re­duced by 47%. Both re­sults were sta­tis­ti­cal­ly sig­nif­i­cant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.